Research Overview
What the preparation is
Ventfort belongs to the cytomax line of tissue-derived peptide preparations. Production involves extracting vessel-wall tissue, removing high-molecular-weight protein and lipid material, and retaining a water-soluble low-molecular-weight peptide fraction. Because the result is a mixture, characterisation reports fraction distribution and identity markers rather than a CAS number, formula or sequence — a point that shapes how findings should be compared between lots and between suppliers.
The peptide bioregulator hypothesis
The theoretical framework behind the series proposes that very short peptides derived from a given tissue can interact with DNA and chromatin-associated proteins and thereby influence the expression of genes relevant to that tissue. Supporting work has reported sequence-dependent binding of short peptides to oligonucleotides and changes in expression markers in cell culture. The hypothesis remains debated, and independent replication outside the originating research group is limited.
Vascular research context
- Endothelial cell cultures examining proliferation, viability and expression markers.
- Isolated vessel preparations and rodent models of age-related vessel-wall change.
- Comparative studies of the extract against the defined synthetic tripeptide Vesugen.
- Ageing biology work in which several organ-specific preparations are assayed in parallel.
Evidence limits
Most of the primary literature is published in Russian-language journals, with small sample sizes and few blinded or independently replicated designs. Batch-to-batch variability is an inherent feature of tissue-derived preparations, so investigators should record lot numbers as an experimental variable and, where the question allows, run the defined synthetic peptide alongside the extract as a controlled comparator.
